Income Statement Presentation 2023

Immunology: Actemra COVID-19 sales declining and Esbriet LOE Xolair autoinjector approval and Ph III food allergy readout expected in 2023 CHFM YoY CER growth 2,500 0% +7% -2% 2,000 -17% 1,500 1,000 500 0 Q4 19 Q4 20 Q421 Rituxan/MabThera (RA) Actemra SC CellCept Esbriet Actemra IV Xolair Pulmozyme Other Q4 22 Q4 updates Actemra (-22%) • • COVID-19 related sales declining Shift from IV to SC ongoing, SC share reaches 60% Xolair (+6%) • Roche Market leader in asthma biologics and strong growth in CSU Esbriet (-48%) • US: Generic competition Outlook 2023 • US approval of Xolair autoinjector expected; Ph III • (OUTMATCH) in food allergy to read out ⚫ Ph III ASO factor B in IgAN to be initiated • ⚫ Ph III (INShore) Gazyva in PNS to be initiated CER=Constant Exchange Rates; LOE-loss of exclusivity; RA=rheumatoid arthritis; IV-intravenous; SC=subcutaneous; CSU-chronic spontaneous urticaria; ASO=antisense oligonucleotide; IgAN-immunoglobulin A nephropathy; PNS=pediatric nephrotic syndrome 28

View entire presentation